Literature DB >> 19447476

Testing for occult cancer in patients with pulmonary embolism: results from a screening program and a two-year follow-up survey.

Luis Jara-Palomares1, Consolación Rodríguez-Matute, Teresa Elías-Hernández, José Antonio Rodríguez-Portal, José Luis López-Campos, Hugo Garcia-Ibarra, Emilia Barrot-Cortés, Remedios Otero-Candelera.   

Abstract

INTRODUCTION: An association between pulmonary embolism (PE) and a subsequent diagnosis of cancer has been repeatedly reported. Although screening and early detection might play a pivotal part in reducing mortality from cancer, there are currently no definite data to suggest that cancer screening may improve survival rates in patients with PE. We hereby present the results of a screening program and a two-year follow-up survey for detecting occult cancer in this patient population.
MATERIALS AND METHODS: A total of 107 patients with PE were consecutively enrolled. All subjects underwent an initial screening program followed by a two-year follow-up survey. We calculated the sensitivity of our screening program, and identified risk factors associated with occult cancer by means of logistic regression.
RESULTS: The initial screening program yielded positive results in five patients (4.7%), and four additional cases were identified during the 2-year follow-up. The overall sensitivity of our screening program in idiopathic PE was 55.5%. In the entire study cohort, the number necessary for screening was 12.1 (6.1 in idiopathic PE, and 58 in secondary PE). Logistic regression analysis revealed that a shock index >/=1 (odds ratio: 5.467; p=0.007) and idiopathic PE (odds ratio: 12.82; p=0.03) were independent risk factors for occult cancer in our PE patients.
CONCLUSIONS: A simple and noninvasive screening program yields an acceptable sensitivity for detecting occult cancer in idiopathic PE patients. These results highlight the importance of screening for occult cancer in patients diagnosed with PE, especially in idiopathic forms. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19447476     DOI: 10.1016/j.thromres.2009.04.012

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  2 in total

1.  Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis.

Authors:  Nick van Es; Grégoire Le Gal; Hans-Martin Otten; Philippe Robin; Andrea Piccioli; Ramon Lécumberri; Luis Jara-Palomares; Piotr Religa; Viriginie Rieu; Matthew T Rondina; Mariëlle M Beckers; Paolo Prandoni; Pierre-Yves Salaun; Marcello Di Nisio; Patrick M Bossuyt; Harry R Büller; Marc Carrier
Journal:  BMJ Open       Date:  2017-06-10       Impact factor: 2.692

2.  Performance of 18F-fluorodesoxyglucose positron-emission tomography combined with low-dose computed tomography for cancer screening in patients with unprovoked venous thromboembolism.

Authors:  Philippe Robin; Pierre-Yves Le Roux; Karine Lacut; Benjamin Planquette; Nathalie Prévot-Bitot; Christian Lavigne; Jean Pastre; Adel Merah; Grégoire Le Gal; Pierre-Yves Salaun
Journal:  PLoS One       Date:  2017-06-01       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.